Expression of the forkhead transcription factor FOXP1 is associated both with hypoxia inducible factors (HIFs) and the Androgen receptor in prostate cancer but is not directly regulated by Androgens or hypoxia
- 3 May 2007
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 67 (10) , 1091-1098
- https://doi.org/10.1002/pros.20583
Abstract
BACKGROUND FOXP1 is a member of the winged helix or forkhead transcription factors. Recent studies have indicated possible roles for FOXP1 as a candidate tumor suppressor gene and a potential estrogen receptor (ER) co-regulator in the development of breast cancer. This study investigated whether FOXP1 has a similar relationship to the androgen receptor (AR) in prostate cancer and how these factors relate to the presence of hypoxia. METHODS FOXP1, the AR and various hypoxia-regulated proteins (HIF-1α, HIF-2α, and VEGF) were measured with immunohistochemistry using a tissue microarray constructed from 167 archival radical prostatectomies. Statistical analyses compared the co-expression of these factors both with each other and conventional parameters including patient age, pre-operative prostate specific antigen (PSA), post-operative Gleason score, capsular invasion, surgical margin status, tumor volume, and PSA recurrence. The influence of hypoxia, dihydrotestosterone, and the AR blocker Casodex was investigated in prostate cell lines VCaP and LNCaP in vitro. RESULTS Expression of nuclear FOXP1 was significantly positively correlated with AR (P = 0.0001), hypoxia inducible factor 1α (HIF-1α) (P = 0.01), HIF-2α (P = 0.0001), and vascular endothelial growth factor (VEGF) (P = 0.007) expression. A positive significant relationship was also identified with the post-operative Gleason score (P = 0.03) but not with the other variables, including PSA recurrence (P > 0.05). There was no significant change in expression in FOXP1 protein levels under conditions of hypoxia (0.1%), dihydrotestosterone stimulation (10 or 100 nM), or androgen blockade with Casodex (1, 10, or 50 µM). CONCLUSION These findings suggest that there may be a hormonal and hypoxia independent regulatory mechanism coordinating the expression of HIFs, the AR, and FOXP1 in prostate tumors. Prostate 67: 1091–1098, 2007.Keywords
This publication has 19 references indexed in Scilit:
- Foxp1 is an essential transcriptional regulator of B cell developmentNature Immunology, 2006
- Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentationLeukemia, 2006
- EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1–Independent and HIF-1–Dependent MechanismsCancer Research, 2006
- Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1α expressionLaboratory Investigation, 2006
- t(3;14)(p14;q32) Results in aberrant expression of FOXP1 in a case of diffuse large B‐cell lymphomaGenes, Chromosomes and Cancer, 2005
- FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrationsLeukemia, 2005
- Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathwayOncogene, 2005
- T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphomaLeukemia, 2005
- Foxp1regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturationDevelopment, 2004
- Expression of the Forkhead Transcription Factor FOXP1 Is Associated with Estrogen Receptor α and Improved Survival in Primary Human Breast CarcinomasClinical Cancer Research, 2004